Abstract

The CC chemokine receptor 6 (CCR6) is a potential target for chronic inflammatory diseases. Previously, we reported an active CCR6 structure in complex with its cognate chemokine CCL20, revealing the molecular basis of CCR6 activation. Here, we present two inactive CCR6 structures in ternary complexes with different allosteric antagonists, CCR6/SQA1/OXM1 and CCR6/SQA1/OXM2. The oxomorpholine analogues, OXM1 and OXM2 are highly selective CCR6 antagonists which bind to an extracellular pocket and disrupt the receptor activation network. An energetically favoured U-shaped conformation in solution that resembles the bound form is observed for the active analogues. SQA1 is a squaramide derivative with close-in analogues reported as antagonists of chemokine receptors including CCR6. SQA1 binds to an intracellular pocket which overlaps with the G protein site, stabilizing a closed pocket that is a hallmark of inactive GPCRs. Minimal communication between the two allosteric pockets is observed, in contrast to the prevalent allosteric cooperativity model of GPCRs. This work highlights the versatility of GPCR antagonism by small molecules, complementing previous knowledge of CCR6 activation, and sheds light on drug discovery targeting CCR6.

Small molecule antagonists of CCR6 are potential drugs for autoimmune disorders. Here the authors present inactive structures of CCR6 bound by different allosteric antagonists from two series simultaneously, offering multiple approaches to inhibit CCR6.

Details

Title
Structural basis for CCR6 modulation by allosteric antagonists
Author
Wasilko, David Jonathan 1 ; Gerstenberger, Brian S. 2   VIAFID ORCID Logo  ; Farley, Kathleen A. 1   VIAFID ORCID Logo  ; Li, Wei 3 ; Alley, Jennifer 3 ; Schnute, Mark E. 2   VIAFID ORCID Logo  ; Unwalla, Ray J. 2 ; Victorino, Jorge 1 ; Crouse, Kimberly K. 3 ; Ding, Ru 3 ; Sahasrabudhe, Parag V. 1   VIAFID ORCID Logo  ; Vincent, Fabien 1   VIAFID ORCID Logo  ; Frisbie, Richard K. 1 ; Dermenci, Alpay 4 ; Flick, Andrew 4   VIAFID ORCID Logo  ; Choi, Chulho 4   VIAFID ORCID Logo  ; Chinigo, Gary 4 ; Mousseau, James J. 4 ; Trujillo, John I. 4 ; Nuhant, Philippe 2 ; Mondal, Prolay 4 ; Lombardo, Vincent 4 ; Lamb, Daniel 5 ; Hogan, Barbara J. 5   VIAFID ORCID Logo  ; Minhas, Gurdeep Singh 6 ; Segala, Elena 6 ; Oswald, Christine 6 ; Windsor, Ian W. 1   VIAFID ORCID Logo  ; Han, Seungil 1   VIAFID ORCID Logo  ; Rappas, Mathieu 5 ; Cooke, Robert M. 6 ; Calabrese, Matthew F. 1   VIAFID ORCID Logo  ; Berstein, Gabriel 3 ; Thorarensen, Atli 2 ; Wu, Huixian 1   VIAFID ORCID Logo 

 Pfizer Inc., Discovery Sciences, Medicine Design, Groton, USA (GRID:grid.410513.2) (ISNI:0000 0000 8800 7493) 
 Pfizer Inc., Medicine Design, Cambridge, USA (GRID:grid.410513.2) (ISNI:0000 0000 8800 7493) 
 Pfizer Inc., Inflammation and Immunology Research, Cambridge, USA (GRID:grid.410513.2) (ISNI:0000 0000 8800 7493) 
 Pfizer Inc., Medicine Design, Groton, USA (GRID:grid.410513.2) (ISNI:0000 0000 8800 7493) 
 Great Abington, Sosei Heptares, Steinmetz Building, Granta Park, Cambridge, UK (GRID:grid.410513.2); Great Abington, Nxera Pharma UK Limited, Steinmetz Building, Granta Park, Cambridge, UK (GRID:grid.410513.2) 
 Great Abington, Sosei Heptares, Steinmetz Building, Granta Park, Cambridge, UK (GRID:grid.410513.2) 
Pages
7574
Publication year
2024
Publication date
2024
Publisher
Nature Publishing Group
e-ISSN
20411723
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
3099205420
Copyright
© The Author(s) 2024. This work is published under http://creativecommons.org/licenses/by-nc-nd/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.